Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Conduit Pharmaceuticals ( (CDT) ) has provided an update.
On January 16, 2026, CDT Equity Inc. entered into a directed stock purchase agreement with an institutional investor to establish a $25 million equity line of credit facility, giving the company the right, but not the obligation, to sell common shares over a period of up to 36 months, subject to conditions including a 9.99% ownership cap for the investor and a floor price initially set at $1.35 per share, with periodic adjustments based on Nasdaq trading prices. The arrangement allows CDT Equity to issue stock at discounts to recent volume-weighted average prices within set size limits per closing, with proceeds earmarked for working capital and general corporate purposes, and includes a ban on other at-the-market or equity line financings during the term; as consideration, the company will issue 204,031 commitment shares to the investor and has agreed, via a separate registration rights agreement, to register for resale both the shares issuable under the facility and the commitment shares under the Securities Act, which collectively may affect existing shareholders through future dilution while bolstering the company’s funding flexibility.
More about Conduit Pharmaceuticals
Average Trading Volume: 246,646
Technical Sentiment Signal: Sell
Current Market Cap: $2.4M
Find detailed analytics on CDT stock on TipRanks’ Stock Analysis page.